Radiation therapy alone for medically inoperable patients with adenocarcinoma of the endometrium.
Surgery with adjuvant radiation is the definitive method for treating patients with Stage I and II FIGO endometrial carcinoma. However, radiation therapy alone becomes the only curative alternative for patients who presented with severe, acute, and chronic medical illnesses which prevented surgical management. We report on 104 such patients treated at Centre Alexis Vautrin in Nancy (FRANCE) between 1975 and 1984. The minimum follow-up was 2 years, the maximum was 11 years. Fifty-two patients were treated by association of external irradiation (RT) and curietherapy (CUR), and 52 by curietherapy alone. The median age of the patients was 68.8 years with a minimum of 43 and maximum of 89 years old. Ninety-six patients (92.3%) were obese. Forty-nine (47.1%) were hypertensive. Forty-one (39.4%) had cardiovascular diseases, 25 (24%) had diabetes mellitus, and 13 (12.5%) had history of phlebitis. Seventy-nine patients (75.9%) were Stage I FIGO, 15 (14.4%) were Stage II, 4 patients (3.8%) were Stage III, and 6 patients (5.7%) were Stage IV. The 5- and 10-year overall absolute survival was 51.6% and 35.9% respectively. The 5- and 10-year determinate survival was 65.9% and 58.6% respectively. The 5- and 10-year absolute survival of patients treated by combination RT + CUR was 59.6 and 49.8% respectively. The 5- and 10-year survival of patients treated by CUR alone was 42.3% and 27% significantly worse (p = 0.025). The 5- and 10-year determinate survival for Stage Ia was 82.1%, 71.4% and for Stage Ib 64.6% and 64.6% respectively. The difference was not significant (p = 0.18). While the 5- and 10-year determinate survival for Stage II was 56.2% and 56.3%, significantly worse than Stage I patients (p = 0.043). Tumor differentiation (G) was found to be a significant prognostic factor in survival (p less than 0.05). Local failure was seen in 9 patients (8.6%) 5 in association with distant metastasis (DM). The 5- and 10-year actuarial local control were 87.6% and 85.1% respectively. Severe complications occurred in 18 patients (17.3%). Five of these patients are still alive with a mean follow-up of 8.8 years (minimum 6 years and maximum 11 years). The rate of complications had considerably diminished after 1980, as techniques improved and computerized dosimetry was used.